Last updated on January 2019

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Amyloidosis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Biopsy-proven systemic AL amyloidosis defined as
  • At least one + Congo Red stain
  • Proof of a clonal plasma cell dyscrasia by:
  • Immunofixation electrophoresis (IFE) of the urine or serum
  • Light chain restriction based on Immunohistochemistry (IHC) in bone marrow plasma cells or in the amyloid tissue
  • Must be scheduled to undergo antineoplastic therapy (this may include high dose melphalan and Autologous Stem Cell Transplantation) for AL Amyloidosis (Part II enrollments only)

Exclusion Criteria:

  • Co-existing Multiple Myeloma
  • Prior antineoplastic treatment for AL amyloidosis at time of enrollment.
  • Prior negative bone marrow biopsy showing no identifiable clone

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.